Why Eli Lilly, Novo Nordisk, Zealand Pharma & More are Prioritizing the Amylin-Based Therapeutics Summit
This December, senior teams across biology, preclinical, translational, clinical, medical and business development are coming together to compare how they are approaching the next phase of amylin R&D. With new human data emerging, modality strategies diversifying and receptor-level questions still unresolved, the Amylin-Based Therapeutics Summit offers a focused environment to benchmark programs, challenge assumptions and understand how leading organizations are positioning themselves as the field becomes more competitive.
Attending Companies Include
What's New for 2026?
Decoding the Amylin Receptor Puzzle
A deep-dive workshop tackling one of the field’s biggest unanswered questions: which amylin receptors should next-generation therapies target? Explore receptor selectivity, DACRA strategies, signalling bias and the species-translation challenges shaping drug design.
From Discovery to the First Amylin Medicines
Revisit the scientific journey that transformed amylin from a pancreatic amyloid-associated peptide into a therapeutic hormone, uncovering the foundational pharmacology and development lessons that continue to shape today’s amylin programmes.
Translating Dual GLP-1/Amylin Agonism into Clinical Impact
Explore what the Phase II zenagamtide programme is revealing about combining GLP-1 and amylin receptor agonism, from dose-response and tolerability to receptor balance, patient selection and differentiation from established incretins.
Networking Opportunities Include:
Speed Networking
Make a high volume of relevant introductions in a short space of time, helping you quickly identify the amylin developers, partners and experts most valuable to your work.
Interactive Workshops
Spend three hours in a focused, discussion-led setting with peers tackling the field’s most complex challenges, creating space for deeper technical exchange, candid questions and more meaningful connections.
Roundtable Discussions
Join small-group conversations around shared amylin development challenges, compare approaches with peers and leave with practical insights from companies facing similar scientific and strategic decisions.
Ice Breaker
Start Day 1 with an informal, interactive activity designed to make introductions easier, break down barriers and help you build relationships before the main scientific program begins.
The DACRA Debate
Take part in a structured networking debate around one of the field’s biggest strategic questions: broad DACRA activity versus more selective receptor targeting. Compare scientific rationales, challenge assumptions and connect with peers on both sides of the discussion.
Explore the Full Event Guide
- See the full amylin-focused agenda, from receptor biology and translational challenges through clinical development and commercialization
- Discover the leading amylin programs and case studies being discussed across monotherapy and combination approaches
- Preview insights from the field’s pioneers and key developers, including the scientists shaping next-generation amylin therapeutics
- Benchmark where the field is heading, from receptor selectivity and tolerability to patient positioning and competitive differentiation
- Share one concise overview internally to help colleagues and decision-makers assess the value of attending
Explore the Agenda
Dive into the latest advances in amylin drug development, from receptor biology and translational challenges to clinical differentiation, combination strategies and commercial opportunity through presentations, roundtables and panel discussions.
Partner With Us
Position your company alongside leading amylin developers and showcase the tools, technologies and services helping biopharma accelerate next-generation amylin programmes.
Join Amylin Experts
Connect with the scientists, clinicians and decision-makers shaping the future of amylin therapeutics across discovery, preclinical, clinical and commercial development.